How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about abemaciclib with fulvestrant

Marketing authorisation indication

2.1 Abemaciclib (Verzenios, Eli Lilly) is indicated 'for the treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.'

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics.

Price

2.3 The list price for abemaciclib is £2,950 per 28-day cycle: £1,475 per 28-tablet pack, or £2,950 per 56-tablet pack of 150 mg tablets; £1,475 per 28-tablet pack, or £2,950 per 56-tablet pack of 100 mg tablets; and £1,475 per 28-tablet pack, or £2,950 per 56-tablet pack of 50 mg tablets (excluding VAT; BNF online, accessed January 2021).

2.4 The list price for fulvestrant is £522.41 for two 250 mg/5 ml pre-filled syringes of solution for injection, which equates to £1,044.82 for the first cycle, and £522.41 for subsequent cycles (excluding VAT; BNF online, accessed January 2021).

2.5 The company has a commercial arrangement (simple discount patient access scheme). This makes abemaciclib available to the NHS with a discount and it would have also applied to this indication if the technology had been recommended. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.